Why Novavax Stock More Than Doubled Today [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it. The company is partnering with fellow pharmaceutical company Sanofi (NASDAQ: SNY) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based on Novavax's underlying science used to create its coronavirus jab. Novavax is suddenly a new company For the quarter ending in March, Novavax had $94 million in revenue and a loss of $1.05 per share. These numbers are an improvement on the year-ago loss of $3.41 per share, on $81 million in sales. The top line fell short of estimates of $101 million, and the bottom line was barely better than the expected per-share loss of $1.06. It's a much-needed glimmer of hope from a company that remained in the red during the worst of the pandemic despite being one of the few companies that sold an approved COVID vaccine These results, however, took a back seat to news of the p
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 [Yahoo! Finance]Yahoo! Finance
- Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3GlobeNewswire
- European Stocks Advance After Weekly Drop as Focus Turns to ECB [Yahoo! Finance]Yahoo! Finance
- European Stocks Advance After Weekly Drop as Focus Turns to ECB [BNN Bloomberg (Canada)]BNN Bloomberg
- Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits [MSNBC.com]MSNBC.com
SNY
Sec Filings
- 5/30/24 - Form 6-K
- 5/28/24 - Form 6-K
- 5/28/24 - Form SD
- SNY's page on the SEC website